Hyperleptinemia contributes to antipsychotic drug–associated obesity and metabolic disorders
Science Translational Medicine · 22.11.2023 · 15 (723)
DOI: 10.1126/scitranslmed.ade8460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 22.11.2023. Verfasst von Shangang Zhao und 27 weiteren Autor:innen. Beteiligte Einrichtung: Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Metabolic Diseases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Despite their high degree of effectiveness in the management of psychiatric conditions, exposure to antipsychotic drugs, including olanzapine and risperidone, is frequently associated with substantial weight gain and the development of diabetes. Even before weight gain, a rapid rise in circulating leptin concentrations can be observed in most patients taking antipsychotic drugs. To date, the contribution of this hyperleptinemia to weight gain and metabolic deterioration has not been defined. Here, with an established mouse model that recapitulates antipsychotic drug–induced obesity and insulin resistance, we not only confirm that hyperleptinemia occurs before weight gain but also demonstrate that hyperleptinemia contributes directly to the development of obesity and associated metabolic disorders. By suppressing the rise in leptin through the use of a monoclonal leptin-neutralizing antibody, we effectively prevented weight gain, restored glucose tolerance, and preserved adipose tissue and liver function in antipsychotic drug–treated mice. Mechanistically, suppressing excess leptin resolved local tissue and systemic inflammation typically associated with antipsychotic drug treatment. We conclude that hyperleptinemia is a key contributor to antipsychotic drug–associated weight gain and metabolic deterioration. Leptin suppression may be an effective approach to reducing the undesirable side effects of antipsychotic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Sam and Ann Barshop Institute for Longevity and Aging Studies, Division of Endocrinology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
- Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
- Center for Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Division of Endocrinology and Metabolism, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
- College of Life Sciences, Wuhan University, Wuhan, Hubei Sheng 430072, China.
ORCID-Profile: Shangang Zhao, Qian Lin, Wei Xiong, Li Li, Leon Straub, Dinghong Zhang, Rizaldy Zapata, Qingzhang Zhu, Xue-Nan Sun, Zhuzhen Zhang, Jan-Bernd Funcke, Chao Li, Yi Zhu, Nisi Jiang, Guannan Li, Ziying Xu, Steven C Wyler, Juli Bai, Xianlin Han, Ningyan Zhang, Zhiqiang An, Philipp E Scherer
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
Zitieren
APA
Zhao, S., Lin, Q., Xiong, W., Li, L., Straub, L., Zhang, D., Zapata, R., Zhu, Q., Sun, X. N., Zhang, Z., Funcke, J. B., Li, C., Chen, S., Zhu, Y., Jiang, N., Li, G., Xu, Z., Wyler, S. C., Wang, M. Y., …, & Scherer, P. E. (2023). Hyperleptinemia contributes to antipsychotic drug–associated obesity and metabolic disorders. Science Translational Medicine, 15(723). https://doi.org/10.1126/scitranslmed.ade8460
Vancouver
Zhao S, Lin Q, Xiong W, Li L, Straub L, Zhang D, et al. Hyperleptinemia contributes to antipsychotic drug–associated obesity and metabolic disorders. Science Translational Medicine. 2023;15(723). doi:10.1126/scitranslmed.ade8460
BibTeX
@article{Zhao2023,
author = {Zhao, Shangang and Lin, Qian and Xiong, Wei and Li, Li and Straub, Leon and Zhang, Dinghong and Zapata, Rizaldy and Zhu, Qingzhang and Sun, Xue-Nan and Zhang, Zhuzhen and Funcke, Jan-Bernd and Li, Chao and Chen, Shiuhwei and Zhu, Yi and Jiang, Nisi and Li, Guannan and Xu, Ziying and Wyler, Steven C and Wang, May-Yun and Bai, Juli and Han, Xianlin and Kusminski, Christine M and Zhang, Ningyan and An, Zhiqiang and Elmquist, Joel K and Osborn, Olivia and Liu, Chen and Scherer, Philipp E},
title = {Hyperleptinemia contributes to antipsychotic drug–associated obesity and metabolic disorders},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {723},
doi = {10.1126/scitranslmed.ade8460}
}
EUVIMED